title: [New oral anticoagulant drugs].
abstract: Thromboembolic disease (TED) is the leading cause of morbidity and mortality worldwide. The hallmark of oral long-term anticoagulant therapy has been the use of vitamin K antagonists, whose anticoagulant effect is exerted inhibiting vitamin K epoxide reductase. Warfarin and acenocoumarol are the most commonly used. In the last five years several new drugs for long term anticoagulation have been developed, which can inhibit single clotting factors with the purpose of improving drug therapeutic range and, ideally, minimizing bleeding risks. This review addresses the state of the art on the clinical use of inhibitors of activated factor X and thrombin.
authors.affiliation: Sección Hemostasia-Trombosis, Departamento de Hematología-Oncología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. aberkovi@uc.cl
authors.forename: Alejandro
authors.initials: A
authors.lastname: Berkovits
authors.forename: Andrés
authors.initials: A
authors.lastname: Aizman
authors.forename: Pamela
authors.initials: P
authors.lastname: Zúñiga
authors.forename: Jaime
authors.initials: J
authors.lastname: Pereira
authors.forename: Diego
authors.initials: D
authors.lastname: Mezzano
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000145:classification*; D065427:Factor Xa Inhibitors; D006801:Humans; D013917:Thrombin / Q000037:antagonists & inhibitors*; D014812:Vitamin K / Q000037:antagonists & inhibitors*
chemical_list: D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D014812:Vitamin K; D013917:Thrombin